<DOC>
	<DOCNO>NCT02911298</DOCNO>
	<brief_summary>This Phase I , open label , single-site trial evaluate vivo release characteristic gastrointestinal tract metronidazole benzoate capsule design disintegrate large intestine . This examine mean metronidazole plasma level scintigraphic image healthy subject . Overall , nine subject evaluate formulation prototype . Two formulation prototype investigate . Each subject receive one radio-labelled capsule .</brief_summary>
	<brief_title>Pharmaco-Scintigraphic Study Evaluate Release Profile Metronidazole Benzoate Capsules</brief_title>
	<detailed_description />
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1 . Healthy subject , male nonpregnant , nonlactating female , 18 55 year old . Females child bear potential must negative urine pregnancy test prior intake study drug , must use hormonal ( oral , implantable injectable ) double barrier method birth control throughout study . Females unable bear child must documentation source record ( i.e. , tubal ligation , hysterectomy , postmenopausal minimum one year since last menstrual period ) . 2 . Ability subject participate fully aspects clinical trial . 3 . Voluntary sign informed consent must obtain document . 4 . Accept use kind tobacco , include cigarette ECigarettes pipe smoking , nicotine replacement oral tobacco consume alcohol drug screen , treatment follow two day . 1 . Participating clinical study involve investigational drug dosage form within previous 30 day . 2 . Radiation exposure clinical trial , include present study diagnostic Xray exclude background radiation , exceed 5 mSv last five year . No subject whose occupational exposure monitor participate study . 3 . Any nuclear medicine procedure prior study day 1 might interfere scintigraphic image acquire . 4 . Clinically significant deviation biochemistry haematology parameter normal range 5 . History gastrointestinal surgery , exception appendectomy unless perform within previous 12 month . 6 . Clinically relevant cardiovascular , renal , hepatic , metabolic , autoimmune , pulmonary particularly gastrointestinal disease , especially peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's disease Irritable Bowel Syndrome ( within previous 12 month ) . 7 . Acute diarrhoea constipation 14 day predict first study day . If screening occurs &gt; 14 day first study day , criterion determine first study day . Diarrhoea define passage liquid faeces and/or stool frequency great three time per day . Constipation define failure defecate frequently every three day . 8 . History adverse reaction allergy metronidazole study drug formulation components/ingredients . 9 . Hypersensitivity imidazole derivative 10 . History malignancy remove adequately treat . 11 . History alcohol drug abuse . 12 . Donation blood ( plasma ) within previous three month donation Plasma last 14 day . 13 . Overthecounter ( OTC ) prescription medication ( include laxative , vitamins natural herbal remedy include St. John 's Wort ) screen visit ( visit 1 ) completion study . Occasional paracetamol acetylsalicylic acid permit . 14 . Ingestion grapefruit juice , coffee , caffeine contain beverage treatment day . 15 . Failure satisfy Investigator participate reason . 16 . Known allergy crustacean ( due Chitosan )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>